- Patent Title: Combining adenovirus and checkpoint inhibitors for treating cancer
-
Application No.: US17141463Application Date: 2021-01-05
-
Publication No.: US11690913B2Publication Date: 2023-07-04
- Inventor: Tuuli Ranki , Sari Anneli Pesonen , Magnus Jäderberg , Elina Haavisto , Lukasz Kuryk , Antti Vuolanto
- Applicant: TARGOVAX OY
- Applicant Address: FI Espoo
- Assignee: TARGOVAX OY
- Current Assignee: TARGOVAX OY
- Current Assignee Address: FI Espoo
- Agency: Nixon Peabody LLP
- Agent Elizabeih Baio; Nicole D Kling
- Priority: EP 188301 2016.09.12
- Main IPC: A61K35/761
- IPC: A61K35/761 ; A61K39/395 ; A61K39/00 ; A61P35/00 ; C07K16/28 ; C07K14/535
Abstract:
The invention relates to the combination therapy comprising oncolytic adenovirus vector and a checkpoint inhibitor or checkpoint inhibitors. More specifically, the invention relates to oncolytic adenovirus vector and checkpoint inhibitor or checkpoint inhibitors for use in a cancer therapy.
Public/Granted literature
- US20210121564A1 COMBINING ADENOVIRUS AND CHECKPOINT INHIBITORS FOR TREATING CANCER Public/Granted day:2021-04-29
Information query
